[Iron, copper and iron/copper index in the serum during remission of acute leukemia in children].

In 57 children in remissions of acute lymphoblastic leukaemia 217 determinations of serum iron (Fe) and copper (Cu) levels were done. In 85% of cases serum Fe and Cu were determined simultaneously with bone marrow examination. Raised mean Cu level in complete remission (20.

Serum iron level in acute lymphoblastic leukaemia.

Serum iron level (SIL) was studied by atomicabs orption spectrophotometry in 57 children with acute lymphoblastic leukaemia. SIL depended on the activity of the disease. Mean SIL was highest in untreated children.

Immunostimulatory effect of zinc in patients with acute lymphoblastic leukemia.

The studies have been performed in 27 ALL patients, aged 4 to 21 years, during their first remission induced by the Memphis Center therapeutic schedule (New Eng. J. Med.

Serum copper investigations in children with acute lymphoblastic leukemia.

Serum copper level (SCL) was studied in 57 children with acute lymphoblastic leukemia (ALL) by atomic absorption spectrophotometry. It was found that changes in serum copper are to a greater extent related to the clinical course of ALL than to the age of the children examined. The highest mean SCL were obtained in untreated patients (261.

Relationship between serum copper and bone marrow blasts in acute leukaemia.

Investigation of serum copper level (SCL) and bone marrow obtained on the same day from 45 children with acute lymphoblastic leukaemia (ALL) showed a highly significant correlation between SCL and marrow blasts. The increase of SCL was associated with the progress of ALL and the elevation of the marrow parablast percentage. The highest mean SCL level was observed in cases displaying full marrow involvement with concomitant hyperleukocytosis and/or leukaemic tumours.

Immunoglobulin and granulocyte cytochemical reactions in L-asparaginase treated children with acute lymphoblastic leukemia.

The dose-dependent effect of L-asparaginase (Crasnitin, Bayer) on the serum IgG, IgA and IgM content was studied in 14 children with acute lymphoblastic leukemia. This effect was less evident in the intracellular metabolism of peripheral blood granulocytes (studied by the NBT test), in the myeloperoxidase and alkaline phosphatase activities and in the serum glycogen and lipid content.

Immunological aspects of L-asparaginase treatment in children with lymphoproliferative disease.

14 children with acute lymphoblastic leukemia and 6 with lymphosarcoma were treated in 13 cures with 300-500 IU/kg bodyweight/day of L-asparaginase and in 11 cures with 501-760 IU/kg/day. An increase of all fractions of immunoglobulins with maximal values at the end of the cures was observed in the group treated with low doses. In the children receiving the high doses of this drug, an increase was observed only in the first 3 or 4 days of therapy and a decrease occurred at the end of the cure.

[Repeated, 2-10 fold asparaginase treatments in children with lymphoproliferative diseases].

In 42 children being in the advanced stage of an acute lymphoblastic leukaemia as well in 7 children with lymphosarcoma a total of 83 series of treatment with L-asparaginase were carried out. During the first blastic crisis of acute leukaemia 74% of complete or partial remissions could be obtained by two treatments and 52% by the following ones. The best results were obtained by organ manifestations of acute leukaemia (80% of complete or partial remissions).

[Immunological aspects in the L-asparaginase treatment of children with lymphoproliferative diseases].

A group of 20 children, including 14 with acute lymphoblastic leukemia and 6 with lymphosarcoma, was studied. 24 cures of l-asparaginase therapy were carried out. The increase of serum immunoglobulin (IgG, IgA, IgM) levels was found in children treated with smaller (from 300 to 500 I.